A nasal COVID-19 vaccine developed by US biotech CyanVac has produced encouraging results in an early trial, showing potential to offer broader immunity and easier delivery than current injections.

The US Food and Drug Administration (FDA) has provided an update on the risk of myocarditis after receiving an mRNA COVID-19 ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

NPR's Pien Huang speaks with pediatrician Alexandra Cvijanovich and Professor Jason L. Schwartz about trying to shore up ...

In addition, after receiving a delisting notice from Nasdaq, Vaxart has requested a hearing before a Nasdaq Hearings Panel pursuant to the procedures set forth in the Nasdaq Listing Rule 5800 Series.

The global Vaccines Market is estimated to be valued at USD 54.50 billion in 2025 and is projected to reach USD 111.3 billion by 2035, registering a compound annual growth rate (CAGR) of 7.4% over the ...

On the heels of a 10-win season in 2024, Lane Kiffin's squad will definitely have a new feel to it heading into 2025.

Tesla and Lucid face Q2 delivery woes as EV demand risks rise. Click to explore TSLA and LCID strategies ahead of tax credit ...

The one constant in Matt Solter’s childhood was baseball, now as an adult, he fights to keep the sport in his life.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

MLSE president and CEO Keith Pelley asked if Masai Ujiri’s departure was his decision or an Edward Rogers decision: That ...